Weight Loss

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

GSK
GSKLONDON, United Kingdom
1 program
Alli® 60 mgN/A1 trial
Active Trials
NCT02141230Withdrawn0Est. Feb 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKAlli® 60 mg

Clinical Trials (1)

NCT02141230GSKAlli® 60 mg

Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.

Start: Dec 2015Est. completion: Feb 20160
N/AWithdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space